Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Genetic test, fMRI may predict cognitive decline: New study

A genetic blood test known as APOE e4 test in combination with functional MRI can successfully predict cognitive decline in healthy adults, according to a study conducted by researchers at Wayne State University, US.

For the study, researchers used APOE e4 allele and a functional MRI (fMRI) on 78 healthy elders.

The study results showed that APOE e4 allele test alone correctly classified 61.5% of participants who would develop cognitive decline, while the combination of APOE e4 allele and fMRI correctly classified 78.9% of the participants.

Among the participants who were predicted to develop cognitive decline, 35% of them showed significant cognitive decline 18 months post-testing.

The APOE e4 allele test is designed to identify the APOE e4 allele, a known genetic marker for Alzheimer’s disease, and fMRI that reveals how the brain is activated during mental tasks.